Why the study?
Heart failure affects over 64 million people globally, and patients discharged after acute decompensated heart failure face a vulnerable phase with elevated risk of adverse outcomes, especially during the first 90 days.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This article discusses the role of natriuretic peptides in optimizing the management of heart failure patients during the vulnerable post-discharge phase.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Villacorta et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: